{"id":"rmc-6236","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RMC-6236 binds covalently to the mutant KRAS G12C protein, preventing its interaction with downstream effectors and blocking proliferative signaling. This mechanism is designed to selectively target tumors harboring KRAS G12C mutations, which are common in non-small cell lung cancer, colorectal cancer, and other solid tumors. The drug aims to provide clinical benefit in patients whose cancers depend on this specific oncogenic driver.","oneSentence":"RMC-6236 is a selective inhibitor of KRAS G12C mutations that blocks oncogenic signaling in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:32.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer with KRAS G12C mutation"},{"name":"Colorectal cancer with KRAS G12C mutation"},{"name":"Other solid tumors with KRAS G12C mutation"}]},"trialDetails":[{"nctId":"NCT07492680","phase":"PHASE2","title":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-07-17","conditions":"Solid Tumors","enrollment":260},{"nctId":"NCT06445062","phase":"PHASE1, PHASE2","title":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-05-24","conditions":"Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma","enrollment":1130},{"nctId":"NCT06881784","phase":"PHASE3","title":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2025-05-06","conditions":"NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC","enrollment":420},{"nctId":"NCT06162221","phase":"PHASE1, PHASE2","title":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-01-18","conditions":"Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer","enrollment":616},{"nctId":"NCT06360354","phase":"PHASE1","title":"A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-05-29","conditions":"Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers","enrollment":350},{"nctId":"NCT06128551","phase":"PHASE1, PHASE2","title":"Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2023-11-14","conditions":"Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":534},{"nctId":"NCT07252232","phase":"PHASE3","title":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2025-12-15","conditions":"Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":500},{"nctId":"NCT06625320","phase":"PHASE3","title":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-10-16","conditions":"Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":501},{"nctId":"NCT06922591","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","status":"RECRUITING","sponsor":"Tango Therapeutics, Inc.","startDate":"2025-05-31","conditions":"PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC","enrollment":183},{"nctId":"NCT05379985","phase":"PHASE1, PHASE2","title":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2022-05-31","conditions":"Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":754},{"nctId":"NCT06040541","phase":"PHASE1","title":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2023-09-07","conditions":"Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":604}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RMC-6236","genericName":"RMC-6236","companyName":"Revolution Medicines, Inc.","companyId":"revolution-medicines-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RMC-6236 is a selective inhibitor of KRAS G12C mutations that blocks oncogenic signaling in cancer cells. Used for Non-small cell lung cancer with KRAS G12C mutation, Colorectal cancer with KRAS G12C mutation, Other solid tumors with KRAS G12C mutation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}